Detalhe da pesquisa
1.
Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy.
Regul Toxicol Pharmacol
; 111: 104553, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843592
2.
Revisiting Activation of and Mechanism of Resistance to Compound IQG-607 in Mycobacterium tuberculosis.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158273
3.
Preclinical safety evaluation of IQG-607 in rats: Acute and repeated dose toxicity studies.
Regul Toxicol Pharmacol
; 86: 11-17, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28232042
4.
Toxicological profile of IQG-607 after single and repeated oral administration in minipigs: An essential step towards phase I clinical trial.
Regul Toxicol Pharmacol
; 90: 78-86, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838610
5.
Construction of Mycobacterium tuberculosis cdd knockout and evaluation of invasion and growth in macrophages.
Mem Inst Oswaldo Cruz
; 112(11): 785-789, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29091140
6.
Effects of tafenoquine against active, dormant and resistant Mycobacterium tuberculosis.
Tuberculosis (Edinb)
; 128: 102089, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34004588
7.
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
Biomed Pharmacother
; 139: 111672, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33965731
8.
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
J Med Chem
; 62(3): 1231-1245, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30615449
9.
Effect of the bradykinin 1 receptor antagonist SSR240612 after oral administration in Mycobacterium tuberculosis-infected mice.
Tuberculosis (Edinb)
; 109: 1-7, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29559112
10.
Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing.
Int J Antimicrob Agents
; 51(3): 378-384, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843821
11.
Preclinical pharmacokinetic profiling of IQG-607, a potential oral metallodrug to treat tuberculosis.
Eur J Pharm Sci
; 111: 393-398, 2018 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29037995
12.
Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis.
PLoS One
; 13(8): e0202568, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30114296
13.
Inhibitory activity of pentacyano(isoniazid)ferrate(II), IQG-607, against promastigotes and amastigotes forms of Leishmania braziliensis.
PLoS One
; 12(12): e0190294, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29281707
14.
Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme.
Sci Rep
; 7: 46696, 2017 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28436453
15.
Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection.
Int J Antimicrob Agents
; 48(2): 203-7, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27364701
16.
IQG-607 abrogates the synthesis of mycolic acids and displays intracellular activity against Mycobacterium tuberculosis in infected macrophages.
Int J Antimicrob Agents
; 43(1): 82-5, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24139881
17.
Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Int J Antimicrob Agents
; 40(2): 182-5, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22748570